Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Eisai
< Previous
1
2
Next >
Lecanemab Receives Priority Review Status in Japan
January 29, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
January 09, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
January 09, 2023
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
December 22, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
December 19, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
December 14, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
December 01, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
November 29, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
November 23, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
April 01, 2022
From
Eisai
Via
ACN Newswire
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 29, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
November 22, 2022
From
Eisai
Via
JCN Newswire
Tickers
ESALY
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
March 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
March 22, 2022
From
Eisai
Via
ACN Newswire
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
March 15, 2022
From
Eisai
Via
ACN Newswire
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
March 15, 2022
From
Eisai
Via
ACN Newswire
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
February 25, 2022
From
Eisai
Via
ACN Newswire
Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
February 01, 2022
From
Eisai
Via
ACN Newswire
Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
January 31, 2022
From
Eisai
Via
ACN Newswire
Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
January 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
January 28, 2022
From
Eisai
Via
ACN Newswire
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
January 20, 2022
From
Eisai
Via
ACN Newswire
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
January 19, 2022
From
Eisai
Via
ACN Newswire
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
January 19, 2022
From
Eisai
Via
ACN Newswire
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
January 17, 2022
From
Eisai
Via
ACN Newswire
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
January 13, 2022
From
Eisai
Via
ACN Newswire
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
January 06, 2022
From
Eisai
Via
ACN Newswire
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
December 24, 2021
From
Eisai
Via
ACN Newswire
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
December 21, 2021
From
Eisai
Via
ACN Newswire
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
December 20, 2021
From
Eisai
Via
ACN Newswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright